The plateau at month six: what to do, what not to do

Almost every patient on tirzepatide hits a stretch somewhere around month five or six where the scale stops moving. Two weeks. Sometimes three. Sometimes a small upward bounce that feels like you're going backwards. The instinct, especially in patients who've been losing reliably for the prior four months, is to push the dose higher to break through. That instinct is usually wrong, and acting on it is the single most common reason patients get into trouble in the second half of year one.

Here's why the plateau happens.

Your body's caloric needs at month one were calibrated to your starting weight. At month six, you've lost 12-18% of body weight. Your basal metabolic rate has adjusted downward proportionally. The same dose of medication, producing the same level of appetite suppression, is now keeping you at a lower caloric intake that exactly matches your new lower metabolic needs. Net energy balance is roughly zero. The scale doesn't move because the math has rebalanced.

This is a feature of the medication working correctly, not a sign that it's failing.

The trial data backs this up. The SURMOUNT-1 trial showed weight loss continuing through month 17 on the same dose, but most of the loss happened in the first six months. The remaining 11 months showed a smaller monthly drop. Some patients showed multi-week stretches of zero loss within that period. None of them were dose escalation candidates; their bodies were simply finding a new equilibrium.

What pushing the dose higher actually does at month six. The dose-response curve for tirzepatide flattens at higher doses. Going from 7.5mg to 10mg to 12.5mg gives diminishing returns on appetite suppression. What it doesn't flatten on is side effects, which scale roughly linearly with dose. So pushing higher in the plateau gives you marginally more suppression at a meaningfully worse side-effect profile. Patients who push through often find themselves miserable for two weeks, get to a slightly lower weight, and then plateau again at the higher dose. They've paid a real cost in tolerability for a small gain.

The patients who do better at month six take the plateau as data, not as a problem to solve. The data is: my body has adjusted to this dose. The choices that follow:

If your weight is at or near a level you're happy with, the plateau IS the answer. You've reached your new set point. The next phase is figuring out the lowest maintenance dose that holds it, which is a step-down conversation, not a step-up one.

If your weight is meaningfully above where you want to be, the conversation is about whether the medication's contribution has plateaued at a level that's not enough on its own. Dose escalation might still help (sometimes it does), but the higher-leverage moves at this stage are usually outside the medication. Resistance training to build lean mass, which raises basal metabolic rate. Protein intake at 1.4-1.6g/kg, which improves satiety beyond what the medication provides. Sleep quality. Strength work in particular shows up in the data as the variable most strongly correlated with continued loss after month six.

If you've been pushing dose hard during the first six months and you're already at 12.5mg or 15mg, there isn't much room left to escalate. You've used up that lever. The lifestyle inputs are now the only remaining ones.

The other thing that can help in the plateau is a brief diet refresh. Not a crash. A two-week period of paying closer attention than usual to what you're eating, especially the snack-foods that creep back in around month five when the food noise from early treatment has quieted. Some patients discover they've been eating 200-300 calories more per day than they realized, distributed across small things. Trimming that for two weeks is often enough to break the plateau without any dose change.

What I would not do at month six: switch medications because tirzepatide "stopped working." It hasn't stopped working. Your body adjusted. Switching to semaglutide will give you a few weeks of restart effect (dose-up to a new molecule, transient appetite suppression) and then you'll plateau at semaglutide's lower-efficacy ceiling. You'll have spent six weeks of GI side effects to end up worse off.

If your prescriber suggests a dose increase at month six without first asking whether you're at a weight you're happy with, push back. The right question is "what are we trying to achieve" before "how do we achieve more." Most month-six plateaus are signaling completion, not failure.